Pioglitazone [20], semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) [21], tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA) [22], and tofogliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i) [23], have all been shown to improve liver function in participants with liver dysfunctions, including NAFLD, NASH (MASH), and hepatic fibrosis, as demonstrated in randomized controlled trials (RCTs). The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.